Growth Disorders Completed Phase 3 Trials for Mecasermin (DB01277)

Also known as: Growth Disorder

IndicationStatusPhase
DBCOND0028940 (Growth Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00125164Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyTreatment